Previous Close | 0.8637 |
Open | 0.8600 |
Bid | 0.8311 x 1000 |
Ask | 0.8525 x 1200 |
Day's Range | 0.8260 - 0.8680 |
52 Week Range | 0.8200 - 4.6400 |
Volume | |
Avg. Volume | 114,356 |
Market Cap | 37.156M |
Beta (5Y Monthly) | N/A |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.4580 |
Earnings Date | Aug 10, 2022 - Aug 15, 2022 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 5.02 |
LAVAL, Québec, June 22, 2022 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”) (Nasdaq: ACST and TSX-V: ACST), a late-stage, specialty pharma company with drug delivery capability and technologies addressing rare and orphan diseases, today announced the annual grant of performance stock options to its employees and executives. An aggregate of 1,212,500 stock options were granted to certain employees and executives of the Company under the Company’s stock option plan (“Stock Opti
Company to Host Conference Call Today at 1:00pm ET LAVAL, Québec, June 21, 2022 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”) (Nasdaq: ACST and TSX-V: ACST), a late-stage, specialty pharma company with drug delivery capability and technologies addressing rare and orphan diseases, today announced financial and operational results for the fiscal year ended March 31, 2022. Recent Highlights Acasti’s 3 lead programs are on schedule to initiate new clinical trials in the second h
Call to be held on Tuesday, June 21st at 1:00 PM Eastern TimeLAVAL, Quebec, June 16, 2022 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”) (NASDAQ: ACST and TSX-V: ACST), today announced that it will host a conference call at 1:00 PM Eastern Time on Tuesday, June 21, 2022, to discuss the Company’s corporate progress and other developments, as well as financial results for fiscal year 2022 ended March 31, 2022. The conference call will be available via telephone by dialing toll